{"id":19101,"date":"2024-10-18T14:00:00","date_gmt":"2024-10-18T08:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19101"},"modified":"2025-05-08T12:46:04","modified_gmt":"2025-05-08T07:16:04","slug":"antipsychotics-for-schizophrenia-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment","title":{"rendered":"How are Antipsychotics Transforming the Schizophrenia Treatment Space?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f39fd0ec5c2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f39fd0ec5c2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\/#Schizophrenia_Multimodal_Treatment_Strategy\" >Schizophrenia Multimodal Treatment Strategy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\/#The_Goal_of_Schizophrenia_Treatment\" >The Goal of Schizophrenia Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\/#Key_Differences_Between_First_and_Second_Generation_Antipsychotics\" >Key Differences Between First and Second Generation Antipsychotics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\/#Compliance_of_Schizophrenia_Patients\" >Compliance of Schizophrenia Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\/#Schizophrenia_Treatment_Landscape\" >Schizophrenia Treatment Landscape<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Schizophrenia affects approximately <strong>24 million<\/strong> people worldwide, or <strong>1 in every 300 people (0.32%)<\/strong>. In adults, this rate is <strong>1 in 222 (0.45%)<\/strong>. It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women.<\/p>\n\n\n\n<p>Schizophrenia is frequently associated with significant distress and impairment in important areas of life such as personal, family, social, educational, occupational, and other. People with schizophrenia are twice as likely as the general population to die young. This is frequently due to physical illnesses such as cardiovascular, metabolic, and infectious diseases.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>According to DelveInsight&#8217;s 2023 analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-epidemiology-forecast\">schizophrenia prevalence<\/a> across the 7MM reached around <strong>4 million<\/strong> diagnosed cases, with the US accounting for <strong>1.5 million<\/strong>. In the EU4 and UK, cases were further divided by severity, with severe accounting for the highest number of cases. Looking ahead, global advancements in psychiatric research and diagnostics are anticipated to boost precise schizophrenia identification by 2034.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>A person with schizophrenia can have symptoms like delusions, hallucinations, disorganized speech, trouble with thinking, and might feel demotivated. It is a disorder with variable phenotypic expression and poorly understood, complex etiology, involving a major genetic contribution, as well as environmental factors interacting with the genetic susceptibility.<\/p>\n\n\n\n<p>Despite its antiquity, most of what is known about schizophrenia has been discovered over the past 10 decades, mostly in the late twenties<strong> <\/strong>and<strong> <\/strong>early twenty-first centuries. A lot of research has been going on to give a clearer picture of the illness. However, despite a century of research, the <a href=\"https:\/\/www.delveinsight.com\/blog\/schizophrenia-market\">pathophysiology of schizophrenia<\/a> remains elusive.<\/p>\n\n\n\n<p>Diagnostic scales, which have been extensively validated, are widely used within clinical practice and research settings. Two key examples include the <strong>American Psychiatric Association\u2019s Diagnostic and Statistical Manual (DSM)<\/strong> and the <strong>World Health Organization\u2019s International Classification of Diseases (ICD)<\/strong>.<\/p>\n\n\n\n<p>Both the <strong>DSM,<\/strong> for which at least two schizophrenia symptoms including delusions, hallucinations, disorganized speech and behavior, and negative symptoms need to have been present for at least six months and for a significant portion of time over one month, and the <strong>ICD<\/strong> for which at least two schizophrenia symptoms must be present, including positive, negative, depressive, manic, psychomotor, and cognitive symptoms. Of the two schizophrenia symptoms, one core symptom needs to be present. Schizophrenia symptoms should have been present most of the time during a period of at least one month. These criteria are regularly updated, and the most recent versions are the <strong>DSM-5<\/strong> and the <strong>ICD-11.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-schizophrenia-multimodal-treatment-strategy\"><span class=\"ez-toc-section\" id=\"Schizophrenia_Multimodal_Treatment_Strategy\"><\/span><strong>Schizophrenia Multimodal Treatment Strategy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite therapeutic advancements in recent decades, schizophrenia remains one of the most severe mental illnesses, with a chronic relapsing course and significant functional impairment in a significant number of individuals. Currently, there is no cure for schizophrenia. However, the disorder is treated and manageable with a <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-pipeline-insight\">combination of schizophrenia therapies<\/a>. Although the aim of treatment of schizophrenia varies depending on severity and phase, but the short-term primary goal of schizophrenia treatment is to control symptoms. The primary goal is to manage psychotic symptoms and enhance patients\u2019 quality of life (QoL). However, the long-term objective of treatment of schizophrenia is to achieve stability and avoid sickness return.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"321\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-1024x321.png\" alt=\"Schizophrenia-Management-Strategy\" class=\"wp-image-31929\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-1024x321.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-300x94.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-150x47.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-768x241.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-1536x481.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123433\/Schizophrenia-Management-Strategy-2048x642.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Goal_of_Schizophrenia_Treatment\"><\/span><strong>The Goal of Schizophrenia Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current pyramid of interventions in managing schizophrenia includes <strong>antipsychotic medications,<\/strong> the most commonly prescribed schizophrenia drugs and thought to control symptoms by affecting the brain neurotransmitter dopamine. Even after symptoms have faded, schizophrenia requires lifetime therapy. Apart from schizophrenia medications, <strong>psychological counseling, and social support, cognitive behavioral therapy and electroconvulsive therapy (ECT)<\/strong> can be used to control the condition. Hospitalization may be required in some circumstances.<\/p>\n\n\n\n<p>Schizophrenia treatment is generally guided by a psychiatrist with expertise in treating schizophrenia, including a psychologist, social worker, or psychiatric nurse. Although therapy objectives such as response, remission, and recovery have become more generally defined, a reliable &#8220;effectiveness&#8221; metric that maps onto functional outcomes remains missing. Furthermore, the field must progress in translating measurement-based techniques from research to clinical practice. Adding to this debate is continuous disagreement about whether first-generation or second-generation antipsychotics should be used.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"426\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-1024x426.png\" alt=\"Schizophrenia-Treatment-Major-Unmet-Need-to-Address\" class=\"wp-image-31931\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-1024x426.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-300x125.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-150x62.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-768x319.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-1536x639.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08123544\/Schizophrenia-Treatment-Major-Unmet-Need-to-Address-2048x852.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Differences_Between_First_and_Second_Generation_Antipsychotics\"><\/span><strong>Key Differences Between First and Second Generation Antipsychotics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Antipsychotics (APs) are the first-line treatment for schizophrenia on the market. These are divided into two categories: <strong>first-generation antipsychotics<\/strong> (FGA; or conventional APs) and <strong>second-generation antipsychotics<\/strong> (SGA) (SGA; or atypical APs). Both first and second-generation antipsychotics differ significantly in their pharmacological profiles and side effects. <\/p>\n\n\n\n<p>First-generation antipsychotics (FGAs), also known as typical antipsychotics, primarily block dopamine D2 receptors, effectively reducing positive symptoms like hallucinations and delusions, but often cause extrapyramidal side effects such as tremors and rigidity. Second-generation antipsychotics (SGAs), or atypical antipsychotics, act on both dopamine and serotonin receptors, providing relief from both positive and negative symptoms with a lower risk of motor side effects.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"430\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-1024x430.png\" alt=\"Schizophrenia-First-Generation-&amp;-Second-Generation-Antipsychotics-Analysis\" class=\"wp-image-31933\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-1024x430.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-300x126.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-150x63.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-768x323.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-1536x645.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124031\/Schizophrenia-First-Generation-Second-Generation-Antipsychotics-Analysis-2048x860.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>These are either administered orally for oral antipsychotics (OAP) or intravenously for long-acting injectable treatment for schizophrenia. Although both first and second-generation antipsychotics are used for <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\">schizophrenia treatment<\/a>, the usefulness of the second generation over the first is controversial, as is the effectiveness of LAI over OAP.<\/p>\n\n\n\n<p>However, when evaluating individual adverse effect profiles, the distinction between first and second-generation antipsychotics as unified classes cannot be maintained, requiring a more differentiated approach and schizophrenia treatment decision. The intended, tailored schizophrenia treatment strategy must take present symptoms, comorbid diseases, previous therapeutic responses, adverse effects, and patient preference and expectations into account.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"265\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-1024x265.png\" alt=\"Approved-Drugs-for-Schizophrenia-Treatment\" class=\"wp-image-31934\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-1024x265.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-300x78.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-150x39.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-768x199.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-1536x397.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124231\/Approved-Drugs-for-Schizophrenia-Treatment-2048x530.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Today, at the global level, some of the key companies, such as <strong>Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmac\u00e9uticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Luye Pharma, Newron Pharmaceuticals,<\/strong> and others, are evaluating various new antipsychotics in different schizophrenia clinical trials to improve the treatment space.&nbsp;<\/p>\n\n\n\n<p>Currently, the therapies in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-pipeline-insight\" class=\"ek-link\">schizophrenia pipeline<\/a> include <strong>IIclepertin (BI-425809), Ulotaront (SEP-363856), Brilaroxazine (RP5063), Roluperidone (MIN-101\/MT-210), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), OKEDI\/RISVAN (risperidone ISM), Olanzapine LAI (mdc-TJK\/TV-44749), Valbenazine (NBI-98854), LYN-005 (long-acting oral risperidone), Evenamide (NW-3509), LY03010 (ER paliperidone palmitate), <\/strong>and others. The launch of these schizophrenia treatment medications in the coming years will significantly improve people\u2019s lives affected by schizophrenia.<\/p>\n\n\n\n<p>Moreover, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-epidemiology-forecast\">global prevalence of schizophrenia<\/a> has observed stable growth in the past two decades, and the same stable growth is expected in the coming years. Governments and health organizations must raise awareness to make schizophrenia patients comfortable to combat mental illness and raise awareness of the long-term repercussions. However, due to the side effects of the antipsychotic schizophrenia medication, compliance is quite less, and it is a challenge for the caregivers to tackle this issue. Despite antipsychotic therapy, schizophrenia is linked with considerable unmet medical demands, functional impairments, and a high burden of illness. One of the biggest impediments to treatment effectiveness in schizophrenia is medication non-compliance. Non-adherence is prevalent, with outcomes including insufficient symptom management, relapse, hospitalization, and increased consumption and expense of health care resources.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Compliance_of_Schizophrenia_Patients\"><\/span><strong>Compliance of Schizophrenia Patients<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Schizophrenia patients who stop using antipsychotic medications maybe two to five times are more likely to relapse than other schizophrenia patients. Although the causes for medication non-adherence are varied, the failure to stay on schizophrenia medicine jeopardizes the chance of remission and better functioning in people with schizophrenia. To date, <strong>clozapine<\/strong> is the only evidence-based treatment for refractory schizophrenia patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear at best.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"358\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-1024x358.png\" alt=\"Compliance-to-Schizophrenia-Treatment\" class=\"wp-image-31936\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-1024x358.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-300x105.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-150x53.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-768x269.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-1536x538.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124335\/Compliance-to-Schizophrenia-Treatment-2048x717.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schizophrenia_Treatment_Landscape\"><\/span><strong>Schizophrenia Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To discover <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/schizophrenia-newsletter\" class=\"ek-link\">novel schizophrenia treatment medication<\/a> with enhanced\/broader efficacy and improved tolerability, and to enable personalized treatment, the mechanisms underlying illness development and progression, symptomatic improvement, and side effect development need to be elucidated. Most people with schizophrenia benefit from combined antipsychotic medication and non-pharmacologic treatments that address their personal goals. Several promising approaches for improving outcomes in schizophrenia are under study that may help mitigate persistent psychotic symptoms, negative symptoms, and cognitive deficits in patients with established illnesses. Attention is being focused on the early administration of psychosocial interventions to reduce persistent disability.<\/p>\n\n\n\n<p>Nevertheless, after over a century of schizophrenia treatment, significant progress has been made, starting from the lobotomy operations, through the discovery of chlorpromazine, to current second and third- generation antipsychotics. Novel approaches, following new studies in the disease mechanisms, will finally result in a new generation of schizophrenia drugs.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"587\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-1024x587.png\" alt=\"Evolving-Schizophrenia-Treatment-Landscape\" class=\"wp-image-31938\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-1024x587.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-300x172.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-150x86.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-768x440.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-1536x881.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08124437\/Evolving-Schizophrenia-Treatment-Landscape-2048x1174.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>As per DelveInsight analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\">schizophrenia market size<\/a> in the 7MM is expected to change during the study period (2020\u20132034). In 2023, the total schizophrenia market size was <strong>USD 8 billion<\/strong>, which is expected to rise by 2034.<\/em><\/p>\n\n\n\n<p>Furthermore, the <strong>WHO\u2019s Comprehensive Mental Health Action Plan 2013\u20132030<\/strong> will raise mental health awareness by ensuring that <strong>100 million <\/strong>more people have access to quality and affordable mental health care.<\/p>\n<\/blockquote>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-1024x194.png\" alt=\"Schizophrenia Market Outlook\" class=\"wp-image-30090\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18140609\/Schizophrenia-Market-Outlook-8.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women. Schizophrenia is frequently [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1519,16707,16708,16709,19795,19796,16710,19797],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-19101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-schizophrenia","tag-schizophrenia-market","tag-schizophrenia-pipeline","tag-schizophrenia-prevalence","tag-schizophrenia-symptoms","tag-schizophrenia-therapies","tag-schizophrenia-treatment","tag-schizophrenia-treatment-market","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antipsychotics: Changing Paradigm for Schizophrenia Treatment<\/title>\n<meta name=\"description\" content=\"The dynamics of the schizophrenia treatment market expected to change as key companies are evaluating lead assets to improve treatment space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antipsychotics: Changing Paradigm for Schizophrenia Treatment\" \/>\n<meta property=\"og:description\" content=\"The dynamics of the schizophrenia treatment market expected to change as key companies are evaluating lead assets to improve treatment space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T08:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T07:16:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antipsychotics: Changing Paradigm for Schizophrenia Treatment","description":"The dynamics of the schizophrenia treatment market expected to change as key companies are evaluating lead assets to improve treatment space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment","og_locale":"en_US","og_type":"article","og_title":"Antipsychotics: Changing Paradigm for Schizophrenia Treatment","og_description":"The dynamics of the schizophrenia treatment market expected to change as key companies are evaluating lead assets to improve treatment space.","og_url":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-10-18T08:30:00+00:00","article_modified_time":"2025-05-08T07:16:04+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment","url":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment","name":"Antipsychotics: Changing Paradigm for Schizophrenia Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market.png","datePublished":"2024-10-18T08:30:00+00:00","dateModified":"2025-05-08T07:16:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The dynamics of the schizophrenia treatment market expected to change as key companies are evaluating lead assets to improve treatment space.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/antipsychotics-for-schizophrenia-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market.png","width":466,"height":284},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18144821\/schizophrenia-treatment-market-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Schizophrenia market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Schizophrenia Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Schizophrenia Prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">schizophrenia symptoms<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">schizophrenia therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Schizophrenia treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">schizophrenia treatment market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">schizophrenia<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia market<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia Prevalence<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia symptoms<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia therapies<\/span>","<span class=\"advgb-post-tax-term\">Schizophrenia treatment<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia treatment market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Oct 18, 2024","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Oct 18, 2024 2:00 pm","modified":"Updated on May 8, 2025 12:46 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19101"}],"version-history":[{"count":9,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19101\/revisions"}],"predecessor-version":[{"id":31940,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19101\/revisions\/31940"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30101"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19101"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19101"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}